SCHEMBL5097548

SCHEMBL5097548

c1cc(OCCCN2CCCCC2)ccc1CNCCN1CCOCC1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 17/20 0.71
▸ KCNH2 Q12809 3/20 0.58
▸ MAPK1 P28482 2/20 0.58
▸ ALDH1A1 P00352 1/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ CHRM2 P08172 1/20 0.58
▸ CHRM1 P11229 1/20 0.58
▸ HTR2A P28223 1/20 0.58
▸ SCN1A P35498 1/20 0.58
▸ HTR2B P41595 1/20 0.58
▸ SCN2A Q99250 1/20 0.58
▸ SIGMAR1 Q99720 1/20 0.58
▸ SCN3A Q9NY46 1/20 0.58
▸ ACHE P22303 1/20 0.58
▸ RAD52 P43351 1/20 0.58
▸ USP2 O75604 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5100664 0.99 HRH3 (0.70) HRH3KCNH2MAPK1ALDH1A1CYP1A2
SCHEMBL14287672 0.95 HRH3 (0.71) HRH3KCNH2MAPK1ALDH1A1CYP1A2
SCHEMBL14287660 0.92 HRH3 (0.68) HRH3ACHERAD52KMT2A
SCHEMBL14287678 0.92 HRH3 (0.68) HRH3ACHERAD52KMT2A
SCHEMBL5107405 0.89 HRH3 (0.64) HRH3ACHERAD52KMT2A
SCHEMBL14287674 0.87 HRH3 (0.68) HRH3ACHERAD52
SCHEMBL3182761 0.87 CYP2C19 (0.68) HRH3ALDH1A1KMT2A
SCHEMBL3175514 0.86 CYP2C19 (0.70) HRH3ALDH1A1KMT2A
SCHEMBL3173535 0.86 CYP2C19 (0.70) HRH3ALDH1A1KMT2A
SCHEMBL3570492 0.83 HRH3 (1.00) HRH3ACHERAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7314937-B2 Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2008-01-01 — — US disclosed
US-7314937-B2 Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2008-01-01 — — US disclosed
US-7314937-B2 Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2008-01-01 — — US disclosed
US-20040110748-A1 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses BEAVERS LISA SELSAM (US) 2004-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110748-A1 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses HRH3, HRH4, HRH2 HRH3 1/4885KCNH2 634/4885MAPK1 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback